Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX)

Core Insights - Immatics N.V. is developing a cell therapy named Anzu-cel (anzutresgene autoleucel, IMA203) targeting melanoma and other potential cancers, which could generate hundreds of millions or more in annual revenue [1] Company Overview - The company has already produced some data regarding Anzu-cel, indicating progress in its development [1] Market Focus - The focus is on trading around significant events such as trial results and NDA/BLA approvals, particularly in the biotech sector regulated by the FDA [1]